16 Dec 2024: Biocytogen announces Adcendo ApS exercises antibody option to accelerate ADC development
Biocytogen Pharmaceuticals announced that Adcendo ApS has exercised its option under a research, option, and license agreement to use Biocytogen’s fully human antibodies to expand its ADC pipeline
Biocytogen’s RenMice® platform is being leveraged in this collaboration to discover fully human antibodies with high affinity, low immunogenicity, and favorable developability
The collaboration aims to support Adcendo’s development of innovative ADC drug candidates for the treatment of cancers with high unmet medical need
Biocytogen, expressed confidence that the collaboration would drive the rapid advancement of novel therapies for global patients
info@ciscientists.com
For a subscription, please provide your email id